Cepheid Obtains CE Marking for Same-Day Diagnostic Equipment

Gonorrhoeae and chlamydia are easily treated once diagnosed and managed. However, according to the European Centers for Disease Control and Prevention (ECDC), the rate of infection for both infections has increased during the last decade.

Current testing materials for both gonorrhoeae and chlamydia are slow and problematic, oftentimes requiring additional tests to confirm diagnosis. The delays and inaccuracies in testing have hampered communication between patients and doctors, leaving patients unaware of their infections and unable to procure treatment.

Cepheid’s new products provide diagnostic results in less than 90 minutes, enabling same-day patient consultation and treatment options.

"We are bringing to market a true next-generation molecular diagnostic product for detection of CT/NG a test designed from the ground up to provide unprecedented accuracy, ease of use, and results availability," said John Bishop, CEO, Cepheid. "We expect these innovative products to deliver new levels of confidence to clinicians making same-day decisions in consulting with, and treating, their patients the critical first step in effectively managing these diseases."

Xpert CT/NG will be immediately available as a CE-marked product and is expected to become available in the United States in late 2012.


Related Links:

Cepheid